刘志伟博士毕业于中国科学院大学上海药物研究所,主修药理学专业。在博士期间,他的工作聚焦在KRAS突变肿瘤的精准治疗策略寻找上。他通过结合基于质谱的蛋白组学技术和包括机器学习等的生信分析手段,对KRAS突变的肿瘤进行分子分型,并找到了潜在的亚型特异性联合用药策略。其工作成果被发表在Cell、Molecular cell等国际顶级期刊上。在2021年7月份,以博士后的身份加入了Guomics团队,致力于蛋白组学大数据的研究。

 

代表性论文:

1. Zhiwei Liu #, Yingluo Liu #, Lili Qian, Shangwen Jiang, Xiameng Gai, Shu Ye, Yuehong Chen, Xiaomin Wang, Linhui Zhai, Jun Xu, Congying Pu, Jing Li, Fuchu He, Min Huang, Minjia Tan. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Molecular cell. 2021,81:1-15(First author)
2. JunYu Xu #, Chunchao Zhang #, Xiang Wang #, Linhui Zhai #, Yiming Ma #, Yousheng Mao, Kun Qian, Changqing Sun, Zhiwei Liu, Shangwen Jiang, Minghui Wang, Lin Feng,Lei Zhao, Ping Liu, Bo Wang, Xin Zhao, Hui Xie, Xiaoyun Yang, Liyuan Zhao, Yafei Chang, Jingya Jia, Xijun Wang, Yimin Zhang, Yaru Wang, Yikun Yang, Zhixiang Wu, Longhai Yang, Bin Liu, Teng Zhao, Shengguo Ren, Aihua Sun, Yang Zhao, Wantao Ying, Fei Wang, Guangshun Wang, Yi Zhang, Shujun Cheng, Jun Qin, Xiaohong Qian, Yi Wang, Jing Li, Fuchu He, Ting Xiao, Minjia Tan. Integrative Proteomic Characterization of Human Lung Adenocarcinoma. Cell. 2020, 182: 245–261 (co-author)
3. Xun Huang #, Juan Yan #, Min Zhang #, Yafang Wang #, Yi Chen, Xuhong Fu , Rongrui Wei , Xing-Ling Zheng, Zhiwei Liu, Xiong Zhang , Hong Yang , Bingbing Hao, Yan-Yan Shen, Yi Su, Xiaoji Cong, Min Huang, Minjia Tan, Jian Ding, Meiyu Geng. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. Cell. 2018;175(1):186-99 e19. (co-author)